Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Cash from Operations (2020 - 2025)

Tarsus Pharmaceuticals has reported Cash from Operations over the past 6 years, most recently at 19330000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 19330000.0 for Q4 2025, up 187.14% from a year ago — trailing twelve months through Dec 2025 was 12451000.0 (up 85.0% YoY), and the annual figure for FY2025 was 12451000.0, up 85.0%.
  • Cash from Operations for Q4 2025 was 19330000.0 at Tarsus Pharmaceuticals, up from 18257000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for TARS hit a ceiling of 20551000.0 in Q2 2021 and a floor of 39335000.0 in Q4 2023.
  • Median Cash from Operations over the past 5 years was 14845000.0 (2022), compared with a mean of 12912650.0.
  • Peak annual rise in Cash from Operations hit 903.72% in 2021, while the deepest fall reached 490.88% in 2021.
  • Tarsus Pharmaceuticals' Cash from Operations stood at 12121000.0 in 2021, then rose by 10.29% to 10874000.0 in 2022, then tumbled by 261.73% to 39335000.0 in 2023, then skyrocketed by 43.61% to 22182000.0 in 2024, then soared by 187.14% to 19330000.0 in 2025.
  • The last three reported values for Cash from Operations were 19330000.0 (Q4 2025), 18257000.0 (Q3 2025), and 29387000.0 (Q2 2025) per Business Quant data.